Remarkable work from @IdoAmitLab: PD-1⁺ Tfh-like cells define a pathological T cell–B cell circuit in MS—and a target for programmable CAR T therapy.
I discuss the study, MrVI, and parallels with CXCL13⁺PD-1⁺ cells in skin: linkedin.com/posts/manuel-g…
I discuss the study, MrVI, and parallels with CXCL13⁺PD-1⁺ cells in skin: linkedin.com/posts/manuel-g…
2/15 Current MS therapies can be highly effective, particularly early in disease, yet some patients continue to accumulate disability. We aimed to identify immune cells that sustain chronic CNS inflammation and develop a therapy that targets them selectively.View quoted post on X